• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amarin Corporation plc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    4/22/24 12:54:42 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRN alert in real time by email
    8-K
    0000897448FalseAMARIN CORP PLC\UK00-000000000008974482024-04-182024-04-18

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of Earliest Event Reported): April 18, 2024

    Amarin Corporation plc

    (Exact name of registrant as specified in its charter)

     

     

     

    England and Wales

    0-21392

    Not applicable

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (I.R.S. Employer

    Identification No.)

     

     

     

     

     

    Iconic Offices, The Greenway, Block C Ardilaun Court,

    112 – 114 St Stephens Green, Dublin 2, Ireland

    Not applicable

    (Address of principal executive offices)

    (Zip Code)

    Registrant’s telephone number, including area code: +353 1 6699 020

     

    Not Applicable

    Former name or former address, if changed since last report

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    Trading Symbol

    Name of each exchange on which registered

    American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc

    AMRN

    NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Item 5.02. Compensatory Arrangements of Certain Officers.

    As described under Item 5.07 of this Current Report on Form 8-K, on April 18, 2024, at the Annual General Meeting of Shareholders (the “Annual Meeting”) of Amarin Corporation plc (the “Company”), the Company’s shareholders approved Amendment No. 3 to the Company’s 2020 Stock Incentive Plan, as amended (the “2020 Plan”) to increase the share reserve under the 2020 Plan by 10,000,000 ordinary shares or ADSs (as defined below), as the case may be (the “Shares”) and to increase the number of Shares that may be issued in the form of incentive stock options by 10,000,000 Shares (the “Plan Amendment No. 3”). The 2020 Plan was originally adopted by the Company’s board of directors on March 16, 2020 and approved by the Company’s shareholders at its 2020 annual general meeting.

    The Company’s officers and directors are among the persons eligible to receive awards under the 2020 Plan in accordance with the terms and conditions thereunder. A detailed summary of the 2020 Plan and the Plan Amendment No. 3 is set forth in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the “SEC”) on March 4, 2024 (the “Proxy Statement” under the caption “Proposal No. 6: Adoption of an Amendment to the Company’s 2020 Stock Incentive Plan,As Amended” which summary is incorporated herein by reference). That detailed summary of the 2020 Plan and the Plan Amendment No. 3, and the foregoing description of the Plan Amendment No. 3, are qualified in their entirety by reference to the full text of the 2020 Plan and the Plan Amendment No. 3, a copy of each of which is filed herewith as Exhibit 10.1 and 10.2, respectively, and which are incorporated herein by reference.

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    The Company held the Annual Meeting on April 18, 2024. The matters set forth below were voted on and approved by the Company’s shareholders at the Annual Meeting. There were approximately 421,174,494 ordinary shares entitled to vote at the Annual Meeting based on the February 20, 2024 record date, of which approximately 401,870,067 were held in the name of Citibank, N.A., which issues Company-sponsored American Depositary Receipts (“ADRs”) evidencing American Depositary Shares (“ADSs”) which, in turn, each represent one ordinary share. Of the ordinary shares entitled to vote, 255,152,802 shares, or approximately 61%, were present and voting in person or by proxy at the Annual Meeting. In accordance with the Company’s Articles of Association, the presence, in person or by proxy, of a quorum for the transaction of business at the Annual Meeting was constituted by at least two shareholders who held shares as of February 20, 2024.

    The matters set forth below were voted on at the Annual Meeting. Detailed descriptions of these matters and voting procedures applicable to these matters at the Annual Meeting are contained in the Proxy Statement. All matters were approved in accordance with the Company’s Articles of Association. Set forth below are the voting results for each matter.

    (1) An ordinary resolution to re-elect Mr. Patrick Holt as a director:

     

    Votes For

    Votes Against

    Abstentions

    Broker Non-

    Votes

    136,073,314

    5,215,323

    2,477,170

    111,386,995

    (2) An ordinary resolution to re-elect Mr. Louis Sterling III as a director:

    Votes For

    Votes Against

    Abstentions

    Broker Non-

    Votes

    131,897,029

    9,379,465

    2,489,313

    111,386,995

    (3) An ordinary resolution to re-elect Ms. Patrice Bonfiglio as a director:

    Votes For

    Votes Against

    Abstentions

    Broker Non-

    Votes

    132,861,738

    8,367,933

    2,536,136

    111,386,995

    (4) A non-binding advisory vote to approve the compensation of the Company’s named executive officers:

    Votes For

    Votes Against

    Abstentions

    Broker Non-

    Votes

    111,449,588

    28,688,121

    3,628,098

    111,386,995

     


     

    (5) An ordinary resolution to appoint Ernst & Young LLP as the Company’s U.S. independent registered public accounting firm for the fiscal year ending December 31, 2024 and U.K. statutory auditors under the Companies Act 2006 (to hold office until the conclusion of the next general meeting at which accounts are laid before the Company), and to authorize the Audit Committee to fix and determine the auditors’ remuneration:

    Votes For

    Votes Against

    Abstentions

    Broker Non-

    Votes

    246,283,751

    6,678,260

    2,190,791

    -

    (6) An ordinary resolution to adopt and approve the proposed amendment to the Company’s 2020 Stock Incentive Plan:

    Votes For

    Votes Against

    Abstentions

    Broker Non-

    Votes

    110,294,057

    25,315,132

    8,156,618

    111,386,995

    (7) A special resolution to authorize and approve, subject to the confirmation of the High Court of Justice in England and Wales, the cancellation of the amount standing to the credit of the share premium account of the Company as at the date of the court hearing:

    Votes For

    Votes Against

    Abstentions

    Broker Non-

    Votes

    135,942,337

    5,743,426

    2,080,044

    111,386,995

    (8) An ordinary resolution to authorize and approve, in accordance with section 694 of the Companies Act 2006, the terms of the share repurchase agreement dated 9 January 2024 and made between the Company and Cantor Fitzgerald & Co.:

    Votes For

    Votes Against

    Abstentions

    Broker Non-

    Votes

    139,181,600

    3,922,810

    661,397

    111,386,995

    (9) A special resolution to authorize and approve the amended and restated articles of association of the Company which eliminate the classified structure of the board of directors and provide that all directors of the Company are required to retire and seek re-election on an annual basis at each future annual general meeting of the Company:

    Votes For

    Votes Against

    Abstentions

    Broker Non-

    Votes

    133,418,475

    6,237,818

    4,109,514

    111,386,995

    Item 8.01. Other Events.

    On April 22, 2024, the Company issued a press release titled “Amarin Announces Results of Annual General Meeting of Shareholders.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No.

    Description

    3.1

    Amended and Restated Articles of Association of the Company

    10.1

    The Amarin Corporation plc 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on July 14, 2020)

     

    10.2

    Amendment No. 3 to the Amarin Corporation plc 2020 Stock Incentive Plan

     

    99.1

    Press Release, dated April 22, 2024

     

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    * * *

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

     

    Date: April 22, 2024

    Amarin Corporation plc

     

     

     

     

    By:

    /s/ Jonathan Provoost

    Jonathan Provoost

    Executive Vice President, Chief Legal & Compliance Officer and Secretary

     

     


    Get the next $AMRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMRN

    DatePrice TargetRatingAnalyst
    11/20/2023Underweight
    JP Morgan
    10/25/2023$3.00 → $1.00Buy → Hold
    Jefferies
    1/6/2023$1.30 → $3.00Hold → Buy
    Jefferies
    5/6/2022Neutral → Underweight
    JP Morgan
    5/5/2022$10.00 → $3.00Outperform → Mkt Perform
    SVB Leerink
    5/5/2022$10.00 → $3.00Buy → Neutral
    H.C. Wainwright
    5/4/2022Outperform → Market Perform
    Northland Capital
    2/16/2022$11.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $AMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Fishman Peter L.

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    4/2/26 4:30:11 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Berg Aaron converted options into 4,179 units of American Depositary Shares and covered exercise/tax liability with 2,298 units of American Depositary Shares, increasing direct ownership by 2% to 82,595 units (SEC Form 4)

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    2/3/26 7:00:09 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Legal Officer Provoost Jonathan

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    2/3/26 7:00:07 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline

    DUBLIN and BRIDGEWATER, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with hypertriglyceridemia be part of a broader dyslipidemia management as discussed in the 2026 American College of Cardiology (ACC) / American Heart Association (AHA)/Multisociety Dyslipidemia Guideline Update.i  These newly-issued, evidenced-based recommendations summarize the clinical role of icosapent ethyl (IPE) in reducing cardiovascular (CV) risk in statin-treated patients with elevated triglycerides (TG) and full

    3/18/26 8:30:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

    DUBLIN and BRIDGEWATER, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced that additional REDUCE-IT patient subgroup analysis and additional mechanistic data on potential multifactorial biologic activities will be presented at the American College of Cardiology's Annual Scientific Session & Expo, March 28-30, 2026, in New Orleans, LA. Featured Amarin-supported abstracts to be presented by academic collaborators (italicized below) at ACC Scientific Sessions 2026 include: Oral Presentation Efficacy of Icosapent Ethyl Among Patients at Extreme Cardiovascular

    3/16/26 8:15:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology

    Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on patient-centered measures of total disease burden DUBLIN and BRIDGEWATER, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted recently published data in the European Journal of Preventive Cardiology showing in a post hoc analysis of the landmark REDUCE-IT study that, among statin-treated participants with elevated triglycerides and known CVD or with di

    3/2/26 8:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    SEC Filings

    View All

    SEC Form PRE 14A filed by Amarin Corporation plc

    PRE 14A - AMARIN CORP PLC\UK (0000897448) (Filer)

    3/30/26 5:57:06 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

    3/27/26 5:00:07 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Amarin Corporation plc

    10-K - AMARIN CORP PLC\UK (0000897448) (Filer)

    3/2/26 5:31:01 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Berg Aaron bought $102,400 worth of Ordinary Shares (160,000 units at $0.64), increasing direct ownership by 25% to 805,380 units (SEC Form 4)

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    8/5/24 5:30:03 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Holt Patrick bought $15,724 worth of Ordinary Shares (14,426 units at $1.09), increasing direct ownership by 5% to 314,426 units (SEC Form 4)

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    1/24/24 4:31:21 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JP Morgan resumed coverage on Amarin

    JP Morgan resumed coverage of Amarin with a rating of Underweight

    11/20/23 7:16:51 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin downgraded by Jefferies with a new price target

    Jefferies downgraded Amarin from Buy to Hold and set a new price target of $1.00 from $3.00 previously

    10/25/23 6:25:52 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin upgraded by Jefferies with a new price target

    Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously

    1/6/23 7:26:32 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Financials

    Live finance-specific insights

    View All

    Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

    Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the fourth quarter and full year ended December 31, 20

    2/25/26 7:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

    DUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth quarter and full year 2025 financial results and conduct a conference call on Wednesday, February 25, 2026. The Company will issue a press release detailing its fourth quarter and full year 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062International dial in: 973-528-0011Acces

    2/11/26 8:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Reports Third Quarter 2025 Financial Results

    Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand, continued success in managing US market, and initial operating margin improvements following corporate rightsizingTargeting sustainable positive free cash flow in 2026 DUBLIN and BRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today announced financial results for the third quarter of 2025. "With the reporting of Q3 2025 we usher in the next phase i

    10/29/25 7:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Leadership Updates

    Live Leadership Updates

    View All

    Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

    DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. "On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared priority to continue focusing on strategies to maximize shareholder value, make him a beneficial addition to the board at this time," said Odysseas Kostas, MD, Chairman of the Board. "I am eager to join the board and begin working with fellow directors and the s

    4/7/25 7:30:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Appoints Peter Fishman Chief Financial Officer

    DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company, effective immediately. He will be responsible for leading Amarin's global finance organization and will report directly to the Company's Chief Executive Officer, Aaron Berg. Most recently, Mr. Fishman served as the Company's Global Controller and principal financial and accounting officer. "Pete brings tremendous experience to his new role at Amarin, including most recently as a trusted advisor to our leadership team serving as principal financial and accounting officer for the Company," said

    12/13/24 9:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Board of Directors Announces CEO Transition

    -- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company. "On behalf of the Company's Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron

    6/4/24 7:30:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Amarin Corporation plc (Amendment)

    SC 13G/A - AMARIN CORP PLC\UK (0000897448) (Subject)

    12/8/23 4:26:23 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Amarin Corporation plc (Amendment)

    SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

    12/5/23 7:30:10 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Amarin Corporation plc (Amendment)

    SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

    9/5/23 4:15:30 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care